MTAA
GPI
Market cap488mUSD
Jul 09, Last price
14.78EUR
1D
1.37%
1Q
-10.75%
Jan 2017
41.44%
IPO
35.60%
Name
GPI SpA
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
GPI S.p.A. delivers specialized IT and high-tech services to the healthcare and social-healthcare markets. The company develops a wide range of software solutions covering critical areas such as health administration, clinical systems, social care, blood and tissue banking, human resource management, continuum care, public administration, safety and prevention, chronic illness management, patient care, business intelligence, data analytics, health cooperation, and people relationship management. Beyond software, GPI delivers key healthcare administration services, including advanced centralized booking and contract systems designed to significantly reduce patient waiting times, alongside innovative healthcare technologies and broader healthcare support. Their product portfolio features the Phasys System, an integrated hardware and software platform for optimizing medication management in healthcare facilities, and the RIEDL Phasys System, which automates medicine distribution within pharmacies. Furthermore, GPI offers general ICT services, payment solutions for both public administration and retail, and a comprehensive suite of desktop services. These desktop services encompass the design, implementation, and ongoing maintenance of technological infrastructures; IT consultancy and support; provision of solutions for public administrations; and help desk and facility management for a diverse clientele including local and central public bodies, healthcare providers, multi-utilities, and private enterprises. They also specialize in trouble ticketing systems and the design of integrated technological solutions. Established in 1988 and headquartered in Trento, Italy, GPI S.p.A. operates as a subsidiary of FM S.r.l.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||